자르텍스 테라퓨틱스(XRTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.97 (+18.67%), 시가총액 $0.00B, 52주 최저~최고 $0.34 ~ $3.03.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is ba
자르텍스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
자르텍스 테라퓨틱스의 현재 주가는 $1.97 (+18.67%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
자르텍스 테라퓨틱스의 시가총액은 약 $0.00B입니다.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-